Журналов:     Статей:        

Рецепт. 2019; : 266-274

Чувствительность к антибиотикам возбудителей внегоспитальной пневмонии и рациональная терапия

Коваленко И. В., Лаптева Е. А., Позднякова А. С., Катибникова Е. И.

Аннотация

Выбор обоснованного антибактериального лечения внегоспитальной пневмонии во избежание ее затяжного течения в настоящее время остается актуальным, несмотря на прогресс фармакотерапии. Антибактериальная терапия в таких случаях предусматривает назначение препаратов, активных в отношении наиболее вероятных возбудителей с учетом региональных данных по устойчивости микроорганизмов. Этиологический фактор определяли при посеве мокроты 240 пациентов при внегоспитальной пневмонии за период 2014-2018 гг. в регионе Минской области. Исследование мокроты пока- зало, что этиологическим фактором внегоспитальной пневмонии определен Str. pneumoniae - 80,0% в ассоциации с H. influenzae - 30%, M. catarrhalis - 70%.Уровень чувствительности к β-лактамам микробной ассоциации пневмококка, выделенного из мокроты за период 2014-2018 гг., колебался от 94,9% (к амоксициллину) до 61,3% (к цефотаксиму ) и 61,2% (к цефтриаксону). По результатам наблюдений левофлоксацин проявил наибольшую активность из хинолонов в отношении штаммов микробной ассоциации Str. pneumoniae, отмечено в среднем 91,4% чувствительных штаммов. Офлоксацин оказывал антибактериальный эффект у 86,3% штаммов. Макролиды также проявили высокую активность в отношении ассоциации выделенных штаммов. Наиболее низкий уровень чувствительности микробной ассоциации наблюдался к эритромицину - 61,7%. Кларитромицин оказывал ингибирующее действие на 91,5% штаммов, азитромицин был эффективен у 71,2% штаммов микробной ассоциации. Этиологическая роль Staph. аureus была подтверждена в 20% случаев. Чувствительность Staph. аureus к β-лактамам колебалась от 61,3% (к амоксициллину) до 61,6% (к цефотаксиму) и 61,2,% (к цефтриаксону). Отмечено в среднем 91,4% чувствительных штаммов к левофлоксацину. Офлоксацин оказывал антибактериальный эффект у 86,3% штаммов. Чувствительность микробной ассоциации к эритромицину составила 64,8%. Кларитромицин оказывал ингибирующее действие на 93,8% штаммов, азитромицин был эффективен у 89,7% штаммов микробной ассоциации. Для проведения эффективной рациональной терапии внебольничной пневмонии необходимо динамическое наблюдение за резистентностью к антибиотикам возбудителей респираторных инфекций. Выбор антибиотика для этиотропной терапии должен базироваться на региональных данных, полученных в результате микробиологического мониторинга.

Список литературы

1. Bisenova N.M. (2015) Analiz antibiotikochuvstvitel’nosti shtammov Str. Pneumoniae, videlennih iz mokroti bol’nih s obostreniyami HOBL [Analysis of the antibiotic susceptibility of Str. pneumoniae strains educed from sputum in patients with COPD exacerbations]. Proceedings of the XLI mezhdunarodnoi nauchno-prakticheskoi konferentsii, Astana.

2. Chuchalin A. (2003) Global’naya strategiya diagnostiki, lecheniya i profilaktiki hronicheskoi obstruktivnoi bolezni legki [Global strategy for diagnosis, treatment, and prevention of chronic obstructive pulmonary disease]. Moscow: Atmosfera, pp. 96.

3. (2011) Dannie pervogo Kongressa stran SNG po ratsional’noi antibiotikoterapii Inspiration [Data of the first CIS countries congress on rational antibiotic therapy Inspiration]. Antibiotikoterapiya, no 15-16, pp. 26-269.

4. Zubkov M. (2007) Sovremennie problemi rezistentnosti pnevmotropnih patogenov [Modern problems of resistance of pneumotropic pathogens]. Pul’monologiya, no 5, pp. 5-13.

5. Kozlov R. (2010) Dinamika antibiotikorezistentnosti Streptococcus pneumoniae v Rossii (po dannim mnogotsentrovogo prospektivnogo issledovaniya PEGAS 2006-2009 gg) [Dynamics of antibiotic resistance Streptococcus pneumoniae in Russia (according to the data of the multicentre prospective study PEGAS, 2006-2009)]. Klin. mikrobiol. antimikrob. himioter., no 4, pp. 32-341.

6. Krechikova O., Kozlov R., Bogdanovich T., Stetsyuk O., Suvorov M. (2000) Videlenie, identifikatsiya i opredelenie chuvstvitel’nosti k antibiotikam Streptococcus pneumoniae [Eduction, identification, and measurement of Streptococcus pneumoniae sensitivity to antibiotics]. Metodicheskie rekomendatsii dlya mikrobiologov [Methodical recommendations for microbiologists]. Moscow.

7. Titov L. Antibiotikorezistentnost’ bakterii: potreblenie antimikrobnih preparatov, assotsiatsiya s rezistentnost’yu i virulentnost’yu [Antibiotic resistance of bacteria: consumption of antimicrobials, association with resistance and virulence]. Profilaktika i lechenie gospital’nih infektsii. Rezistentnost’ mikroorganizmov k himiopreparatam: materiali resp. nauch.-prakt. konf. [Prevention and treatment of hospital infections. Resistance of microorganisms to chemotherapy: materials of republican scientific and practical conference]. Minsk, pp. 7-17.

8. Ob utverzhdenii Instruktsii o poryadke provedeniya monitoringa rezistentnosti klinicheski znachimih mikroorganizmov k antibakterial’nim lekarstvennim sredstvam v organizatsiyah zdravoohraneniya [On approval of the Instruction on the procedure of monitoring the resistance of clinically significant microorganisms to antibacterial medicines in health organizations]. Prikaz № 292 MZ RB ot 16.03.2012.

9. (2012) Antimicrobial resistance surveillance in Europe. Surveillance report. Annual Report of the European Antimicrobial Resistance Surveillance Network. Stockholm, pp. 51-59.

10. Bissenova N., Yergaliyeva A. (2014) Monitoring of antimicrobial resistance respiratory strains of Streptococcus pneumonia. Annual Congress of European Respiratory Society. Abstract’s book, pp. 179.

11. (2015) European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual report of the Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC.

12. Jenkins S., Brown S., Farrell D. (2008) Trends in antimicrobial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicob., no 11, pp. 11.

13. Inoue M., Kaneko K. (2008) Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years (1999-2004). Microb Drug Resist, no 14, pp. 109-117.

Recipe. 2019; : 266-274

Sensitivity to Antibiotics of Pathogens of Community-Acquired Pneumonia and Rational Therapy

Kovalenko I. ., Lapteva E. ., E , Pozdniakova A. .

Abstract

The choice of antibacterial treatment of community-acquired pneumonia in order to avoid its protracted course currently remains relevant, despite the progress of pharmacotherapy. Antibacterial therapy in such cases involves the appointment of drugs that are active against the most likely pathogens, taking into account regional data on the resistance of microorganisms.Determination of etiology was done in study of sputum from 240 patients with community-acquired pneumonia within 2014-2018 in Minsk region. Sputum examination reveals etiological significant strains of Str. pneumoniae - 80.0%, associated with H. influenza - 30%, M. satarrhalis - 70%, Staph. aureus was confirmed in 20% of cases.Average sensitivity to β-lactams of the strains of the microbial association isolated from sputum in the period 2014-2018 ranged from 94.9% (to amoxicillin) to 61.3% (to cefotaxime) and 61.2% (to ceftriaxone). According to the results of the observations, levofloxacin showed the greatest activity of quinolones in relation to the strains of the microbial association Str. pneumoniae, marked average level of 91.4% of sensitive strains. Ofloxacin showed an antibacterial effect in 86.3% of the strains. Macrolides also introduced high activity in relation to the association of isolated strains. The lowest sensitivity level of microbial association was observed to erythromycin - 61.7%. Clarithromycin had an inhibitory effect in 91.5% of the strains; azithromycin was effective in 71.2% of the microbial association strains.Sensitivity to β-lactams of Staph. aureus ranged from 61.3% (amoxicillin) to 61.6% (cefotaxime) and 61.2% (ceftriaxone). It was noted about 91.4% strains susceptible to levofloxacin. Ofloxacin showed antibacterial effect in 86.3% of the strains. The sensitivity of microbial associations to erythromycin was 64.8%. Clarithromycin had inhibitory effect in 93.8% of the strains, azithromycin was effective in 89.7% of microbial association. For effective rational therapy of community-acquired pneumonia, dynamic monitoring of antibiotic resistance of respiratory infection pathogens is necessary. The choice of antibiotic for etiotropic therapy should be based on regional data obtained from microbiological monitoring.
References

1. Bisenova N.M. (2015) Analiz antibiotikochuvstvitel’nosti shtammov Str. Pneumoniae, videlennih iz mokroti bol’nih s obostreniyami HOBL [Analysis of the antibiotic susceptibility of Str. pneumoniae strains educed from sputum in patients with COPD exacerbations]. Proceedings of the XLI mezhdunarodnoi nauchno-prakticheskoi konferentsii, Astana.

2. Chuchalin A. (2003) Global’naya strategiya diagnostiki, lecheniya i profilaktiki hronicheskoi obstruktivnoi bolezni legki [Global strategy for diagnosis, treatment, and prevention of chronic obstructive pulmonary disease]. Moscow: Atmosfera, pp. 96.

3. (2011) Dannie pervogo Kongressa stran SNG po ratsional’noi antibiotikoterapii Inspiration [Data of the first CIS countries congress on rational antibiotic therapy Inspiration]. Antibiotikoterapiya, no 15-16, pp. 26-269.

4. Zubkov M. (2007) Sovremennie problemi rezistentnosti pnevmotropnih patogenov [Modern problems of resistance of pneumotropic pathogens]. Pul’monologiya, no 5, pp. 5-13.

5. Kozlov R. (2010) Dinamika antibiotikorezistentnosti Streptococcus pneumoniae v Rossii (po dannim mnogotsentrovogo prospektivnogo issledovaniya PEGAS 2006-2009 gg) [Dynamics of antibiotic resistance Streptococcus pneumoniae in Russia (according to the data of the multicentre prospective study PEGAS, 2006-2009)]. Klin. mikrobiol. antimikrob. himioter., no 4, pp. 32-341.

6. Krechikova O., Kozlov R., Bogdanovich T., Stetsyuk O., Suvorov M. (2000) Videlenie, identifikatsiya i opredelenie chuvstvitel’nosti k antibiotikam Streptococcus pneumoniae [Eduction, identification, and measurement of Streptococcus pneumoniae sensitivity to antibiotics]. Metodicheskie rekomendatsii dlya mikrobiologov [Methodical recommendations for microbiologists]. Moscow.

7. Titov L. Antibiotikorezistentnost’ bakterii: potreblenie antimikrobnih preparatov, assotsiatsiya s rezistentnost’yu i virulentnost’yu [Antibiotic resistance of bacteria: consumption of antimicrobials, association with resistance and virulence]. Profilaktika i lechenie gospital’nih infektsii. Rezistentnost’ mikroorganizmov k himiopreparatam: materiali resp. nauch.-prakt. konf. [Prevention and treatment of hospital infections. Resistance of microorganisms to chemotherapy: materials of republican scientific and practical conference]. Minsk, pp. 7-17.

8. Ob utverzhdenii Instruktsii o poryadke provedeniya monitoringa rezistentnosti klinicheski znachimih mikroorganizmov k antibakterial’nim lekarstvennim sredstvam v organizatsiyah zdravoohraneniya [On approval of the Instruction on the procedure of monitoring the resistance of clinically significant microorganisms to antibacterial medicines in health organizations]. Prikaz № 292 MZ RB ot 16.03.2012.

9. (2012) Antimicrobial resistance surveillance in Europe. Surveillance report. Annual Report of the European Antimicrobial Resistance Surveillance Network. Stockholm, pp. 51-59.

10. Bissenova N., Yergaliyeva A. (2014) Monitoring of antimicrobial resistance respiratory strains of Streptococcus pneumonia. Annual Congress of European Respiratory Society. Abstract’s book, pp. 179.

11. (2015) European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual report of the Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC.

12. Jenkins S., Brown S., Farrell D. (2008) Trends in antimicrobial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicob., no 11, pp. 11.

13. Inoue M., Kaneko K. (2008) Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years (1999-2004). Microb Drug Resist, no 14, pp. 109-117.